Clinical Trials | November 11, 2025
Teva’s AUSTEDO and AUSTEDO XR demonstrate real-world improvement in patients with tardive dyskinesia
The results demonstrated meaningful reductions in the severity of involuntary movements and notable improvements in patient-reported quality of life
